Search Results for: carcinoid syndrome

If I have been diagnosed with carcinoid syndrome due to a high 5-HIAA & symptoms, but nothing shows on a CT scan, what’s next?

October 17, 2015

If I understand your question correctly, you state that a diagnosis of carcinoid syndrome is suspected because of symptoms and high urine 5-HIAA, but the CT scan is normal and you want to know what other tests should now be done to prove the diagnosis. Failure…

READ MORE

What are the main features of carcinoid syndrome?

October 17, 2015

Flushing and diarrhea. A carcinoid tumor somewhere in the body, which has spread to the liver, produces serotonin, chromogranin A and other substances and usually results in excretion in the urine of increased amounts of 5-HIAA, the breakdown product…

READ MORE

What is Neurokinin B and its relationship to carcinoid syndrome?

October 17, 2015

Neurokinin B is a nonspecific peptide hormonal substance sometimes co-secreted into the blood along with one of the other carcinoid products such as serotonin, chromogranin A, substance P and pancreatic polypeptide.…

READ MORE

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

READ MORE
Carcinoid Syndrome, Lexicon Pharmaceuticals, Telotristat Etiprate Clinical Trial

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

READ MORE
Lexicon Telestar_2

Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome

August 20, 2014

Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…

READ MORE
Hands and smartphone

Mobile Survey for Carcinoid Syndrome Community

January 16, 2014

Carcinoid syndrome patients, caregivers, and advocates in the carcinoid syndrome community are invited to participate in an exclusive mobile survey being conducted by WEGO Health via Truvio.

WEGO Health is an organization committed to empowering…

READ MORE
Telotristat Etiprate Clinical Trial

Discover Something New in Carcinoid Syndrome

November 11, 2013

For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…

READ MORE
Pablo Lapuerta, MD

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

December 4, 2012

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

READ MORE
Lexicon Headquarters

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

April 2, 2012

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

READ MORE